# Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

> **NCT06797817** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Universidad de Almeria** · enrollment: 156 (estimated)

## Conditions studied

- Alzheimer Disease (AD)

## Interventions

- **DIETARY_SUPPLEMENT:** tributyrin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06797817
- **Lead sponsor:** Universidad de Almeria
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2029-09-02
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797817, "Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06797817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*